Human Papillomavirus (HPV)


PUBLISHED: 2018 CATEGORY: Health care providers TYPE: External Link Cost-effectiveness of sex-neutral HPV vaccination in Sweden, accounting for herd immunity and sexual behaviour

Cost-effectiveness of sex-neutral HPV vaccination in Sweden, accounting for herd immunity and sexual behaviour

The aim was to assess cost-effectiveness of expanding the Swedish HPV-vaccination program to include preadolescent boys, by comparing health effects and costs of HPV-related disease, with a sex-neutral vaccination program versus only vaccinating girls.

Authors: Wolff E et al.
Journal Issue: 34
Journal Title: Vaccine
Journal Volume: 36
Publisher: Elsevier

PUBLISHED: 2018 CATEGORY: Health care providers TYPE: External Link Human papillomavirus vaccine for children and adolescents: CPS Position Statement

Human papillomavirus vaccine for children and adolescents: CPS Position Statement

Human papillomavirus (HPV) is known to cause genital warts, cervical cancer, penile cancer, anal cancer and oropharyngeal cancer. In North America, the lifetime cumulative incidence of HPV infection is estimated at more than 70% for all HPV types combined. A safe and effective vaccine against nine HPV types is available. HPV vaccine should be administered routinely to all girls and boys between the ages of 9 and 13 years of age. All youth who have not received the vaccine in a routine program should receive the vaccine in a ‘catch-up’ program. Physicians caring for children and youth should advocate for funding and implementation of universal HPV vaccine programs.

Authors: Salvadori MI
Corporate Authors: Infectious Diseases and Immunization Committee
Publisher: Canadian Paediatric Society

PUBLISHED: 2018 CATEGORY: Les fournisseurs de soins TYPE: External Link Le vaccin contre le virus du papillome humain chez les enfants et les adolescents : Document de principes de la SCP

Le vaccin contre le virus du papillome humain chez les enfants et les adolescents : Document de principes de la SCP

On sait que le virus du papillome humain (VPH) cause des condylomes (des verrues génitales), le cancer du col de l’utérus, le cancer du pénis, le cancer anal et le cancer oropharyngé. En Amérique du Nord, l’incidence cumulative de l’infection par le VPH au cours de la vie est évaluée à plus de 70 % pour tous les types de VPH combinés. Un vaccin sécuritaire et efficace est offert contre neuf types de VPH. Le vaccin contre le VPH doit être administré systématiquement à l’ensemble des filles et des garçons âgés de neuf à 13 ans. Tous les jeunes qui n’ont pas été vaccinés dans le cadre d’un programme systématique devraient participer à un programme de rattrapage. Les médecins qui soignent des enfants et des adolescents devraient préconiser le financement et la mise en œuvre de programmes de vaccination universels contre le VPH.

Authors: Salvadori MI
Corporate Authors: Comité des maladies infectieuses et d'immunisation
Publisher: Société canadienne de pédiatrie

PUBLISHED: 2017 CATEGORY: Les fournisseurs de soins TYPE: External Link Examen de la documentation du CCNI concernant l'immunisation contre le VPH des populations immunodéprimées

Examen de la documentation du CCNI concernant l'immunisation contre le VPH des populations immunodéprimées

Les populations immunodéprimées présentent un risque accru d'être infectées par le virus du papillome humain (VPH) et de développer des cancers liés à cette maladie. Toutefois, d'autres précisions sont requises concernant l'immunogénicité et les résultats liés à l'innocuité de l'immunisation contre le VPH dans les populations immunodéprimées. Afin de remédier à cette lacune, une question de recherche a été élaborée par le groupe de travail sur le VPH du Comité consultatif national de l'immunisation (CCNI) et utilisée pour orienter une analyse documentaire.

Corporate Authors: Comité consultatif national de l'immunisation
Publisher: Agence de la santé publique du Canada

PUBLISHED: 2017 CATEGORY: Health care providers TYPE: External Link Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial

Primary analyses of a study in young women aged 16–26 years showed efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccine against infections and disease related to HPV 31, 33, 45, 52, and 58, and non-inferior HPV 6, 11, 16, and 18 antibody responses when compared with quadrivalent HPV (qHPV; HPV 6, 11, 16, and 18) vaccine. Researchers aimed to report efficacy of the 9vHPV vaccine for up to 6 years following first administration and antibody responses over 5 years.

Authors: Huh W et al.
Journal Issue: 05 September 2017
Journal Title: The Lancet
Publisher: The Lancet

PUBLISHED: 2017 CATEGORY: Adults TYPE: External Link Human papillomavirus (HPV) (US CDC)

Human papillomavirus (HPV) (US CDC)

Provides information for parents, for health care professionals, and for partners and programs on HPV:  prevention, screening, signs and symptoms, vaccinations, HPV vaccine safety, treatment, and the link between HPV and cancer.

Corporate Authors: Centers for Disease Control and Prevention
Publisher: Centers for Disease Control and Prevention

PUBLISHED: 2017 CATEGORY: Health care providers TYPE: External Link Investigating Canadian parents' HPV vaccine knowledge, attitudes and behaviour: a study protocol for a longitudinal national online survey

Investigating Canadian parents' HPV vaccine knowledge, attitudes and behaviour: a study protocol for a longitudinal national online survey

Human papillomavirus (HPV), a sexually transmitted infection, can cause anogenital warts and a number of cancers. To prevent morbidity and mortality, three vaccines have been licensed and are recommended by Canada’s National Advisory Committee on Immunisation (for girls since 2007 and boys since 2012). Nevertheless, HPV vaccine coverage in Canada remains suboptimal in many regions. This study will be the first to concurrently examine the correlates of HPV vaccine decision-making in parents of school-aged girls and boys and evaluate changes in parental knowledge, attitudes and behaviours over time.

Authors: Shapiro GK et al.
Journal Issue: 10
Journal Title: BMJ Open
Journal Volume: 7
Publisher: BMJ Journals

PUBLISHED: 2017 CATEGORY: Health care providers TYPE: External Link NACI Literature Review for HPV Immunization of Immunocompromised Populations

NACI Literature Review for HPV Immunization of Immunocompromised Populations

Immunocompromised populations are at increased risk for HPV infection and for developing HPV-associated cancers. However, additional clarity is required surrounding the immunogenicity and safety outcomes of HPV immunization for immunocompromised populations. To address this information gap, a research question was developed by the National Advisory Committee on Immunization (NACI) human papillomavirus (HPV) Working Group and used to guide a literature review.

Corporate Authors: National Advisory Committee on Immunization
Publisher: Public Health Agency of Canada

PUBLISHED: 2017 CATEGORY: Les fournisseurs de soins TYPE: External Link Recommandations mises à jour sur les vaccins contre le virus du papillome humain (VPH) : Calendrier de vaccination du vaccin nonavalent contre le VPH à deux doses et utilisation des vaccins anti-VPH chez les populations immunodéprimées

Recommandations mises à jour sur les vaccins contre le virus du papillome humain (VPH) : Calendrier de vaccination du vaccin nonavalent contre le VPH à deux doses et utilisation des vaccins anti-VPH chez les populations immunodéprimées

La présente déclaration examine les données probantes concernant un calendrier de vaccination à deux doses du vaccin VPH9 et formule des recommandations; elle résume les données probantes obtenues dans le cadre d’une récente analyse documentaire du CCNI sur l’utilisation des vaccins contre le VPH chez les populations immunodéprimées et formule des recommandations sur l’utilisation du vaccin contre le VPH dans ces groupes.

Corporate Authors: Comité consultatif national de l'immunisation
Publisher: Agence de la santé publique du Canada

PUBLISHED: 2017 CATEGORY: Health care providers TYPE: External Link The other 'H' virus: HPV among gay, bi and other MSM with HIV in Canada

The other 'H' virus: HPV among gay, bi and other MSM with HIV in Canada

Learn about human papillomavirus (HPV) and how it affects gay, bisexual, and other men who have sex with men (MSM) living with HIV.

Presenters:

  • Ann Burchell, PhD, epidemiologist and scientist at St. Michael’s Hospital, Toronto
  • Troy Grennan, MD, physician at the BC Centre for Disease Control, Vancouver

 

Drs. Burchell and Grennan are investigators on the HPV-SAVE Study, a national project funded by the Canadian Institutes of Health Research (CIHR) that examines the role of HPV in HIV transmission and looks at ways to best deliver anal cancer screening, treatment, and vaccination programs for MSM.

The webinar recording reviews the findings from this study, as well as some recent data on epidemiology, prevention, screening and diagnosis, and treatment of HPV-associated dysplasia and cancer among MSM.

Publisher: CATIE